Is Indaptus Therapeutics Stock a Good Investment?

Indaptus Therapeutics Investment Advice

  INDP
Not Rated

Examine Indaptus Therapeutics Stock

Researching Indaptus Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 31.0% of the company shares are held by company insiders. The book value of Indaptus Therapeutics was currently reported as 1.1. The company recorded a loss per share of 1.77. Indaptus Therapeutics last dividend was issued on the 30th of October 2020. The entity had 1:4 split on the 27th of July 2021.
To determine if Indaptus Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Indaptus Therapeutics' research are outlined below:
Indaptus Therapeutics is not yet fully synchronised with the market data
Indaptus Therapeutics may become a speculative penny stock
Net Loss for the year was (15.42 M) with profit before overhead, payroll, taxes, and interest of 0.
Indaptus Therapeutics currently holds about 33.01 M in cash with (13.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Indaptus Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 31.0% of the company shares are held by company insiders

Indaptus Therapeutics Quarterly Liabilities And Stockholders Equity

10.95 Million

Indaptus Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Indaptus Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Indaptus Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
15th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact Indaptus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Indaptus Therapeutics' investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-20
2023-12-31-0.54-0.480.0611 
2023-11-06
2023-09-30-0.55-0.470.0814 
2023-05-11
2023-03-31-0.59-0.510.0813 
2023-03-17
2022-12-31-0.52-0.440.0815 
2022-11-10
2022-09-30-0.53-0.420.1120 
2024-05-08
2024-03-31-0.57-0.450.1221 
2023-08-14
2023-06-30-0.58-0.390.1932 
2021-11-15
2021-09-30-0.55-0.81-0.2647 

Know Indaptus Therapeutics' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Indaptus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Indaptus Therapeutics backward and forwards among themselves. Indaptus Therapeutics' institutional investor refers to the entity that pools money to purchase Indaptus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Morgan Stanley - Brokerage Accounts2024-03-31
884
Bangor Savings Bank2024-03-31
400
Wells Fargo & Co2024-03-31
105
Royal Bank Of Canada2023-12-31
38.0
Jpmorgan Chase & Co2024-03-31
14.0
Group One Trading, Lp2024-03-31
7.0
Qube Research & Technologies2024-03-31
1.0
Bank Of America Corp2024-03-31
0.0
Vanguard Group Inc2024-03-31
256.3 K
Investment House Llc2024-03-31
102.4 K
Geode Capital Management, Llc2024-03-31
54.8 K
Note, although Indaptus Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Indaptus Therapeutics' market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.09 M.

Market Cap

11.36 Million

Indaptus Therapeutics' profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets(1.03)(1.09)
Return On Capital Employed(1.35)(1.28)
Return On Assets(1.03)(1.09)
Return On Equity(1.28)(1.21)
Determining Indaptus Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Indaptus Therapeutics is a good buy. For example, gross profit margin measures Indaptus Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Indaptus Therapeutics' profitability and make more informed investment decisions.
The data published in Indaptus Therapeutics' official financial statements typically reflect Indaptus Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Indaptus Therapeutics' quantitative information. For example, before you start analyzing numbers published by Indaptus accountants, it’s essential to understand Indaptus Therapeutics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Indaptus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Indaptus Therapeutics. Check Indaptus Therapeutics' Beneish M Score to see the likelihood of Indaptus Therapeutics' management manipulating its earnings.

Evaluate Indaptus Therapeutics' management efficiency

Indaptus Therapeutics has return on total asset (ROA) of (0.5817) % which means that it has lost $0.5817 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9806) %, meaning that it created substantial loss on money invested by shareholders. Indaptus Therapeutics' management efficiency ratios could be used to measure how well Indaptus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/16/2024, Return On Tangible Assets is likely to drop to -1.09. In addition to that, Return On Capital Employed is likely to grow to -1.28. At this time, Indaptus Therapeutics' Total Current Liabilities is relatively stable compared to the past year. As of 06/16/2024, Liabilities And Stockholders Equity is likely to grow to about 23.5 M, while Non Current Liabilities Total is likely to drop slightly above 69.7 K.
Last ReportedProjected for Next Year
Book Value Per Share 1.44  1.37 
Tangible Book Value Per Share 1.44  1.37 
Enterprise Value Over EBITDA(0.10)(0.09)
Price Book Value Ratio 1.22  1.29 
Enterprise Value Multiple(0.10)(0.09)
Price Fair Value 1.22  1.29 
Enterprise Value1.6 M1.7 M
The analysis of Indaptus Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Indaptus Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Indaptus Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.227

Indaptus Therapeutics' insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Indaptus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Indaptus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Indaptus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Understand Indaptus Therapeutics' technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Indaptus Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Indaptus Therapeutics' intraday indicators

Indaptus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Indaptus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Indaptus Stock media impact

Far too much social signal, news, headlines, and media speculation about Indaptus Therapeutics that are available to investors today. That information is available publicly through Indaptus media outlets and privately through word of mouth or via Indaptus internal channels. However, regardless of the origin, that massive amount of Indaptus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Indaptus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Indaptus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Indaptus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Indaptus Therapeutics alpha.

Indaptus Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Indaptus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Indaptus Therapeutics Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Indaptus Therapeutics stock to make a market-neutral strategy. Peer analysis of Indaptus Therapeutics could also be used in its relative valuation, which is a method of valuing Indaptus Therapeutics by comparing valuation metrics with similar companies.
 Risk & Return  Correlation

Indaptus Therapeutics Corporate Management

MD MBAChief OfficerProfile
Jeffrey MecklerCEO DirectorProfile
Walt EsqChief OfficerProfile
Michael NewmanChief FounderProfile
Boyan MDChief OfficerProfile

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.